Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE BUSINESS NEWS IN BRIEF
April 8, 2002
-
ARCHIVE RESEARCH AND DEVELOPMENT NEWS IN BRIEF
April 8, 2002
-
ARCHIVE WEBSITE NEWS
April 8, 2002
-
ARCHIVE Novartis Kao to Be Dissolved
April 8, 2002
-
ARCHIVE EFPIA Japan to Strengthen European Makers' Presence
April 8, 2002
-
ARCHIVE Pola Cosmetics Transfers Food Division to Asahi Beer Pharm
April 8, 2002
-
ARCHIVE Committee Members Criticize Korosho's Healthcare Reform Bill
April 8, 2002
-
ARCHIVE Pharmarise to Develop Private Brand Supplements
April 8, 2002
-
ARCHIVE Monkasho to Create WG on Duality of Interest
April 8, 2002
-
ARCHIVE WSMI Congress to Be Held in Tokyo in November
April 8, 2002
-
ARCHIVE NEDO Selects Two Medical Device Projects for Funding
April 8, 2002
-
ARCHIVE Technology Transfer Being Stimulated in Japan: Monkasho Symposium
April 8, 2002
-
ARCHIVE CORPORATE ROUNDUP NEWS IN BRIEF
April 8, 2002
-
ARCHIVE Fuso Ties Up with GAL PHARMA for Cancer Diagnostic Products
April 8, 2002
-
ARCHIVE Fee Is Necessary to Ensure Cooperation in Immediate PMS: Survey
April 8, 2002
-
ARCHIVE WORLD NEWS IN BRIEF
April 8, 2002
-
ARCHIVE Teijin Stops Shipment of Blood Glucose Self-measuring Device
April 8, 2002
-
ARCHIVE Fukujin to Upgrade Customer Support Services
April 8, 2002
-
ARCHIVE Terumo: New Pump Data Management System
April 8, 2002
-
ARCHIVE Cancer Detected, Suspected in 38,873 Individuals: Municipal Cancer Examinations
April 8, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…